WNT signal transduction inhibitor
By synthesizing compound M1, the intranuclear metastasis of β-catenin is inhibited, and the problem that existing anti-tumor drugs are difficult to target WNT signaling pathways is solved, effective inhibition and safety of oral squamous cell carcinoma cells is achieved, and the survival of patients is extended Time and quality of life.
Patent Information
- Application Number
- CN202410732868.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-06
- Publication Date
- 2024-11-08
AI Technical Summary
Existing anti-tumor drugs are difficult to effectively target WNT signaling pathways, resulting in poor treatment of oral squamous cell carcinoma cells and toxic side effects, affecting the patient's survival time and quality of life.
Design and synthesize a new WNT signaling inhibitor, which inhibits the WNT/β-catenin signaling pathway by inducing β-catenin phosphorylation and inhibiting its intranuclear metastasis, specifically through the synthesis of compound M1, using benzenesulfonyl chloride, aniline and The raw materials such as triethylamine were reacted under ice bath conditions and the reaction was monitored by thin layer chromatography.
This inhibitor can effectively inhibit the proliferation and apoptosis of oral squamous cell carcinoma cells, significantly prolong the apoptosis time, and display significant IC50 values in different cell lines, have high safety and targeting, and can inhibit WNT Activation of signaling pathways reduces surgical injuries and improves the quality of life of patients.
Smart Images

Figure CN118908864A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of medical inhibitors, and in particular relates to a WNT signal transduction inhibitor. Background Art
[0002] The WNT signaling pathway is one of the most conserved signaling pathways in the evolution of eukaryotic multicellular organisms. In the early stages of embryonic development, the WNT signaling pathway mainly plays a role in stabilizing the self-renewal of stem cells and regulating cell proliferation, differentiation, and apoptosis; while in adult tissues, its main role is to maintain the dynamic balance of the body's system.
[0003] The WNT signaling pathway is mainly composed of WNT proteins (WNTs), Frizzled family proteins, low-density lipoprotein receptor-related protein (LRP), β-catenin, Dishevelled protein (Dsh / Dvl), Axin, glycogen synthase kinase 3β (GSK-3β) and adenomatous polyposis coli (APC).
[0004] Related research literature on oral squamous cell carcinoma suggests that the disease is related to the WNT signaling pathway. For example, Zhang et al. and Uraguchi et al. found that the expression of WNT ligands was increased in oral squamous cell carcinoma through immunohistochemical staining. Uraguchi et al. also found that the enhancement of WNT ligand expression and signaling can accelerate the progression of cancer by activating EMTs and local invasiveness.
[0005] If the metastasis of tumors can be delayed or blocked, the survival time of patients with advanced cancer will be greatly prolonged. The development of better targeted drugs can help patients with head and neck squamous cell carcinoma reduce the damage caused by surgery, which is of great significance for preserving the organ function of patients and improving their quality of life.
[0006] The current research focus is on studying anti-cancer drugs with good synthetic biology effects and lower drug toxicity and side effects. In order to achieve this goal, the structure of the anti-tumor drugs that have been discovered is modified or reconstructed so that the modified compounds have better targeted therapeutic effects. This is a very common research method in the field of anti-tumor drugs.
[0007] Since the WNT gene was discovered in breast cancer in mice in 1982, many scholars at home and abroad have conducted in-depth research on the WNT signaling pathway. However, it is very regrettable that even with so many studies on the WNT signaling pathway, there is still no suitable drug that can target this signaling pathway and is being promoted and used in clinical practice since the discovery of the WNT gene.
[0008] If the metastasis of tumors can be delayed or blocked, the survival time of patients with advanced cancer will be greatly prolonged. The development of better targeted drugs can help patients with head and neck squamous cell carcinoma reduce the damage caused by surgery, which is of great significance for preserving the organ function of patients and improving their quality of life. Summary of the invention
[0009] To solve the problems raised in the above background technology, the present invention provides a WNT signal transduction inhibitor, which takes the regulatory protein β-catenin, which plays a key role in the conduction process of the classical WNT signal pathway, as a drug target, designs and synthesizes a new WNT inhibitor, thereby inducing apoptosis of squamous cell carcinoma cells.
[0010] To achieve the above object, the present invention provides the following technical solution: a compound having the following structure or a pharmaceutically acceptable salt thereof:
[0011] Preferably, the synthesis method specifically comprises the following steps:
[0012] 1) Weigh benzenesulfonyl chloride and aniline respectively and place them in different containers;
[0013] 2) sealing the container and evacuating the air to make it in a vacuum state;
[0014] 3) adding a solvent into the above container to dissolve benzenesulfonyl chloride and aniline;
[0015] 4) placing the benzenesulfonyl chloride container in an ice bath, adding triethylamine to the benzenesulfonyl chloride container, and stirring to mix;
[0016] 5) extracting aniline reaction raw material, injecting it into a benzenesulfonyl chloride container, and maintaining the ice bath state with rotation and stirring for a certain period of time;
[0017] 6) Using thin layer chromatography on a silica gel plate in a dichloromethane / petroleum ether system, monitor the reaction every half an hour, and terminate the reaction after the benzenesulfonyl chloride has reacted completely.
[0018] Compared with the prior art, the present invention has the following beneficial effects:
[0019] 1. The present invention provides a novel Wnt / β-catenin signaling pathway inhibitor, which can induce β-catenin phosphorylation and inhibit β-catenin nuclear translocation, thereby inhibiting the development of oral squamous cell carcinoma cells by inhibiting the Wnt / β-catenin signaling pathway. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 is the hydrogen spectrum of compound M1 of the present invention;
[0021] Figure 2 This is the carbon spectrum of compound M1 of the present invention;
[0022] Figure 3 The changes in cell activity after adding autosynthesis inhibitors;
[0023] Figure 4 This is the cell morphology under an optical microscope after drug treatment (40× magnification);
[0024] Figure 5 IC of self-synthesized small molecule inhibitors in different cell lines 50 Detection result diagram of
[0025] Figure 6 The figure shows the safety test results of MSAB and M1;
[0026] Figure 7 It is a cell proliferation curve diagram under the action of autosynthesis inhibitor at different concentrations;
[0027] Figure 8 This is a flow cytometry test result of self-synthesized small molecule inhibitors in CAL-27;
[0028] Fig. 9 This is a flow cytometry test result of the self-synthesized small molecule inhibitor in HN6;
[0029] Fig.10 This is a diagram showing the effects of self-synthesized small molecule inhibitors on the activation of the WNT signaling pathway;
[0030] Fig.11 To verify the targeting map of self-synthesized small molecule inhibitors by Western blot;
[0031] Fig.12 This is the intracellular localization map of β-catenin in CAL-27 cells after interference with autosynthesis inhibitors by immunofluorescence detection;
[0032] Fig.13 This is the intracellular localization map of β-catenin in HN6 cells after the interference of autosynthesis inhibitor by immunofluorescence detection; DETAILED DESCRIPTION
[0033] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0034] Embodiment 1:
[0035] Preparation of Compound M1: Ethyl 3-((4-methylphenyl)sulfonamido)benzoate
[0036] Construction of reaction system: The raw materials and reagents required for the construction of the compound system were purchased from commercial suppliers. The raw materials and reagents were of analytical grade and were used without further purification.
[0037] Weigh p-toluenesulfonyl chloride (2 mmol, 381.3 mg) using a high-precision electronic balance, add 408.3 mg to the reaction, place in a 50 ml two-necked flask, and place a clean stirring bar.
[0038] Weigh ethyl m-aminobenzoate (2 mmol, 330.38 mg) and add 367.9 mg to the reaction mixture into a 25 ml single-necked flask.
[0039] Both flasks were sealed with rubber stoppers, the original air in the flasks was evacuated by an oil pump, and a nitrogen balloon was used to protect them under vacuum.
[0040] Inject 3 ml of anhydrous dichloromethane into the double-necked flask and 2 ml of anhydrous dichloromethane into the single-necked flask to dissolve the reaction raw materials.
[0041] Slowly add triethylamine (3mmol, 0.415ml) dropwise in a double-necked flask under ice bath, add 0.4ml for reaction, and stir to mix. A small amount of white smoke is generated when adding triethylamine, wait until the smoke disappears after the addition is completed.
[0042] Use a long needle syringe to draw out the other reaction raw material dissolved in the single-necked flask and inject it into the double-necked flask.
[0043] At this point, the reaction system was completed. After maintaining the ice bath state with rotation and stirring for 4 hours, thin layer chromatography (TLC) was used on a silica gel plate (plate model: MERCKGF254) in a dichloromethane / petroleum ether system to monitor the reaction every half an hour. The reaction was terminated after the benzenesulfonyl chloride was completely reacted.
[0044] Post-treatment: After the reaction is terminated, the reaction solution is diluted with dichloromethane;
[0045] The excess amine can be extracted with 1 mol / L hydrochloric acid solution to generate amine salt which can be dissolved in water and removed;
[0046] TLC spot plate detection, repeated extraction until excess amine is removed;
[0047] The product was extracted with saturated brine three times to remove triethylamine in the reaction system for subsequent purification.
[0048] The extract was rotary evaporated at room temperature to obtain a crude product;
[0049] The crude product was dissolved in 1 ml of dichloromethane and wet-applied to silica gel column chromatography (H300-400 mesh silica gel) with an eluent system of dichloromethane / petroleum ether = 1:3. The purified liquid was collected and rotary evaporated at 40°C to obtain a white solid M1: 217 mg with a yield of 33.9%.
[0050] Purification Characterization: All products were characterized by nuclear magnetic resonance. 13CNMR spectra were recorded at 101MHz (BrukerDPX), 1HNMR spectra were recorded at 400MHz. Chemical shift units are (ppm, δ), proton coupling labels are: singlet / doublet / triplet / quartet / multiplet / broad singlet (s / d / t / q / m / br), the results are as follows Figure 1 and Figure 2 shown.
[0051] 1 HNMR (400MHz, DMSO-d6) δ10.15(d,J=2.1Hz,1H),7.70(q,J=1.8Hz,1H),7.62(dd,J=8.4,1.7Hz,2H),7.57(dt,J=7.6,1.5Hz,1H),7.30(d t,J=8.2,1.6Hz,1H),7.22(ddd,J=10.3,7.9,1.9Hz,3H),4.25(qd,J=7.1,1.5Hz,2H),2.31(d,J=1.5Hz,3H),1.30(td,J=7.1,1.5Hz,3H).
[0052] 13 CNMR(101MHz,DMSO-d6)δ165.63,143.45,138.54,137.00,131.28,129.69,129.27,127.05,124.81,124.45,120.89,60.97,21.47,14.41.
[0053] Table 1: List of target compound structures
[0054]
[0055] Activity studies of inhibitors:
[0056] It should be noted that the experimental methods or experimental conditions used in the experimental examples were all carried out according to conventional methods or manufacturer's instructions unless otherwise specified, and the materials and reagents used in the experimental examples were all available from commercial channels unless otherwise specified.
[0057] 1. Culture of oral squamous cell carcinoma cell lines:
[0058] (1) Cell recovery
[0059] Take out the frozen oral squamous cell carcinoma cell line from the -80℃ refrigerator, quickly place it in a 37℃ water bath and shake it to melt the liquid in the cryopreserved tube as soon as possible; in the clean bench, aspirate the liquid in the tube and add it to a 5ml centrifuge tube, add an equal volume of complete culture medium, put it in a low-speed centrifuge at 1500rpm, centrifuge for 5min, discard the upper liquid after centrifugation, resuspend the cells with 1mL of DMEM culture medium containing 10% FBS, add the cell suspension to a 10cm cell culture dish containing 7mL of DMEM culture medium containing 10% FBS, shake it gently, and place the culture dish in a cell culture incubator at 37℃, 5% CO2 for continued culture.
[0060] (2) Cell culture medium replacement
[0061] When the color of the cell culture medium changes from red to yellow (about 2 days), replace it with fresh cell culture medium.
[0062] (3) Digestion and passaging of oral squamous cell carcinoma cells
[0063] When the cell fusion rate reaches about 80%-90% of the bottom area of the whole dish and the culture fluid turns yellow, the liquid in the dish is sucked out, 2mL of trypsin is added along the wall of the dish, and the dish is placed in the incubator for digestion for 4 minutes. After taking it out, it is placed under a microscope for observation. After the cells shrink and the intercellular gap widens, 2mL of culture fluid is added to stop digestion and blow and mix the cells at the bottom of the dish to disperse the cells into single cells. Then the cell suspension is sucked into a centrifuge tube and placed in a low-speed centrifuge at 1500rpm for 5 minutes. After centrifugation, the upper liquid is discarded, the cells are resuspended in culture fluid, and evenly divided into 4 culture dishes, supplemented with 8mL of culture fluid, and placed in a cell culture incubator for continued cultivation. The absorbance value is continuously detected at fixed points for 7 days to draw a proliferation curve.
[0064] 2. CCK8 cell proliferation curve
[0065] (1) Experimental grouping: NC control group and drug-added group were set up respectively. The experiment was conducted in a 96-well plate. When inoculating cells, 21 replicate wells were set up for each group, and 3 replicate wells were tested at the same time every day (replicate wells were not reused);
[0066] (2) Oral squamous cell carcinoma cells in good condition and in the logarithmic growth phase were digested and prepared into a cell suspension. The cells were seeded into a 96-well plate at 5000 / well (CAL-27) and 3500 / well (HN6) and placed in an incubator. After the cells adhered to the wall, various self-synthesized compounds were added to the desired final concentrations according to the NC group and the drug-added group, and the OD value on day 0 was detected at the same time.
[0067] (3) Add 10 μl of CCK8 to each well and incubate in an incubator for 1 h. Measure the absorbance of each well at a wavelength of 450 nm, take the average value of each group, and make a line graph;
[0068] (4) Each group of experiments was repeated 3 times
[0069] 3. Detection of cell apoptosis by flow cytometry
[0070] (1) Cell preparation: The cells were divided into groups and seeded into 6-well plates at a certain cell density (about 3 × 105 cells / well). After the cells adhered to the plate, drugs were added in groups.
[0071] (2) Cell treatment: First, observe the cell growth status of each well under a microscope, digest with EDTA-free trypsin, and collect the cells. Centrifuge at 800 rpm for 5 minutes. After centrifugation, discard the supernatant and resuspend the cells with sterile cold PBS. Repeat 2-3 times; after the end, resuspend the cells with the Binding buffer in the apoptosis kit.
[0072] (3) Preparation before flow cytometry: Take 100 μl of cell suspension from each group and add 5 μl of Annexin V and 5 μl of PI, mix well, incubate at room temperature in the dark for 15 min, resuspend the cells in 400 μl of Staining Buffer, transfer to the flow tube, and test on the flow cytometer.
[0073] 4. Extraction of total protein
[0074] (1) Collect cells and wash twice with PBS.
[0075] (2) Add 10 μl PMSF (100×) and 5 μl protease inhibitor (200×) to 1 mL of lysis buffer, shake well and place on ice.
[0076] (3) Add 100 μl of the prepared lysis buffer to each well of a 6-well culture dish and lyse the cells on ice for 30 minutes.
[0077] (4) Use the yellow tip to scrape all the cells thoroughly in a circular motion, collect the lysate into a clean EP tube, centrifuge at 12,000 g for 10 min at 4°C, and transfer the supernatant to a clean EP tube.
[0078] (5) Determination of protein concentration by BCA method: Take 10 μl of BSA protein standard (5 mg / ml) and dilute it to 100 μl with 1× PBS to a final concentration of 0.5 mg / ml.
[0079] (6) Add 0, 1, 2, 4, 8, 12, 16, and 20 ml of the standard to a 96-well plate, and make up to 20 μl with 1× PBS. Add 2 μl of protein sample to a well of the 96-well plate, and make up to 20 μl with 1× PBS. Add 200 μl of BCA working solution to each well and incubate at 37°C for 30 min.
[0080] (7) Use an ELISA reader to measure the absorbance at a wavelength of 550 nm, and calculate the protein concentration of each sample based on the standard protein curve obtained from the standard concentration and absorbance values. Then add 1 / 5 volume of 5× loading buffer, denature in a 100℃ metal bath for 5 min, and store in a -20℃ refrigerator.
[0081] 5. Western Blot
[0082] (1) Select a suitable precast gel according to the protein molecular weight. Calculate the volume of solution for 40 μg protein according to the protein content, which is the loading amount. Thaw the sample and mix it evenly, then add the protein marker and each group of samples in turn.
[0083] (2) Electrophoresis: Electrophoresis was performed at a constant voltage of 110 V until the front edge of the bromophenol blue dye was electrophoresed out of the end of the gel, and then the electrophoresis was stopped.
[0084] (3) Place a transfer clip, two sponge pads, and two filter papers in a plate with pre-cooled transfer solution. Soak the PVDF membrane in methanol for more than 30 seconds. Install them in the order of "negative electrode clip - sponge - filter paper - rubber block - PVDF membrane - filter paper - sponge - positive electrode clip". Do not leave bubbles between each layer. Place them in the transfer tank and fill it with transfer solution. Determine the transfer time according to the molecular weight of the protein and transfer at a constant voltage of 100V.
[0085] (4) After transfer, the PVDF membrane was appropriately cut and marked, and then placed in 5% BSA blocking solution, with the protein side facing up, and slowly shaken on a shaker at room temperature for 1 hour.
[0086] (5) Incubate with primary antibody. Remove the PVDF membrane strips from the blocking solution and wash them three times with 1× TBST for 5 min each time. Then, place the strips in the corresponding primary antibody incubation solution according to the size of the strips and incubate them in a 4°C refrigerator overnight.
[0087] (6) Incubate with secondary antibody. After the primary antibody incubation is completed, remove the strips, wash them three times with 1× TBST for 5 min each time, and then incubate them in the secondary antibody incubation solution for 1 h.
[0088] (7) Development: Prepare SuperSignalWest PicoPLUS Chemiluminescent Substrate (a mixture of solution A and solution B in a ratio of 1:1) as developer and develop the image on a chemiluminescence detector.
[0089] 6. Dual luciferase reporter plasmid analysis
[0090] 6.1 Plasmid bacterial seed preservation:
[0091] (1) Spread the original colony on an LB plate containing 50 μg / mL ampicillin and incubate it upside down in a 37°C incubator overnight.
[0092] (2) Isolate a single colony and inoculate it into 1-2 mL LB liquid medium containing 50 μg / mL ampicillin.
[0093] (3) Cultivate overnight at 37°C in a shaker at 250 rpm until the bacterial solution reaches the mid-stage (OD600 = 0.5-0.7).
[0094] (4) Mix 0.5 mL of culture with 0.5 mL of sterile glycerol and transfer to low temperature conditions and store at -80°C.
[0095] 6.2 Plasmid amplification and extraction
[0096] (1) Column equilibration step: Add 500 μl of equilibration solution BL to the adsorption column CP3 (the adsorption column is placed in the collection tube), centrifuge at 12,000 rpm (~13,400 × g) for 1 min, pour out the waste liquid in the collection tube, and put the adsorption column back into the collection tube. (Use the column that has been treated on the same day)
[0097] (2) Take 1-5 ml of overnight cultured bacterial solution and add it to a centrifuge tube. Centrifuge at 12,000 rpm (~13,400 × g) for 1 min. Remove the supernatant as much as possible (if the bacterial solution is large, you can collect the bacterial precipitate in one centrifuge tube through several centrifugations).
[0098] (3) Add 250 μl of solution P1 (please check whether RNase A has been added) to the centrifuge tube containing the bacterial cell pellet and use a pipette or vortex oscillator to thoroughly suspend the bacterial cell pellet.
[0099] (4) Add 250 μl of solution P2 to the centrifuge tube and gently invert it upside down 6-8 times to fully lyse the bacteria and make the bacterial solution clear and viscous.
[0100] (5) Add 350 μl of solution P3 to the centrifuge tube and immediately gently invert the tube 6-8 times to mix thoroughly. A white flocculent precipitate will appear. Centrifuge at 12,000 rpm (~13,400 × g) for 10 min.
[0101] (6) Use a pipette to carefully transfer the supernatant to the adsorption column CP3 (place the adsorption column in the collection tube), centrifuge at 12,000 rpm (~13,400×g) for 30-60 seconds, discard the collected waste liquid, and place the adsorption column CP3 in the collection tube.
[0102] (7) Add 500 μl of deproteinized solution PD to the adsorption column CP3, centrifuge at 12,000 rpm (~13,400 × g) for 30-60 sec, discard the waste liquid in the collection tube, and place the adsorption column CP3 in the collection tube.
[0103] (8) Add 600 μl of rinse solution PW to the adsorption column CP3 (check whether anhydrous ethanol has been added), centrifuge at 12,000 rpm (~13,400×g) for 30-60 seconds, discard the collected waste liquid, and place the adsorption column CP3 in a collection tube.
[0104] (9) Repeat step 8.
[0105] (10) Place the adsorption column CP3 into a collection tube and centrifuge at 12,000 rpm (~13,400 × g) for 2 min.
[0106] (11) Place the adsorption column CP3 in a clean centrifuge tube, add 50-100 μl of elution buffer TB to the middle part of the adsorption membrane, leave it at room temperature for 2 min, centrifuge at 12,000 rpm (~13,400 × g) for 2 min, and collect the plasmid solution in the centrifuge tube.
[0107] 6.3 Transfection and dual luciferase activity assay
[0108] Stable 293T cells were inoculated into 24-well plates and cultured for 12 to 24 hours. When the cell density reached 70% to 80%, 250 ng of Top-Flash plasmid and 50 ng of Renilla luciferase vector plasmid were co-transfected into the cells using Lipofectamine 2000, with 2 replicate wells per group. The cells were cultured at 37°C, 5% CO2, and saturated humidity.
[0109] At 48 hours after transfection, 100 μl of cell lysis buffer (PLB) was used to lyse the cells in each well. After mixing, 40 μl was taken out for detection using the dual luciferase reporter gene detection system: first, 40 μl of LuciferaseAssayReagent was added, and after mixing, the value of the fluorescence released by the substrate stimulated by firefly luciferase (Fireflyluciferase) was detected (U1); then 40 μl of Stop&GloReagent was added to quench the firefly fluorescence, and after mixing, the value of the fluorescence released by the substrate stimulated by Renilla luciferase (Renillaluciferase) was detected (U2).
[0110] 7. Cell Immunofluorescence
[0111] (1) Wash the slides with cells in the culture plate three times with PBS, each time for 3 min;
[0112] (2) Fix the slides with 4% paraformaldehyde for 15 min and wash the slides with PBS three times, each time for 3 min;
[0113] (3) 0.5% TritonX-100 (prepared in PBS) at room temperature for 20 min;
[0114] (4) Wash the slides with PBS three times for 3 min each time, dry the PBS with absorbent paper, add normal goat serum on the slides, and block at room temperature for 30 min;
[0115] (5) Remove the blocking solution with absorbent paper. Without washing, add a sufficient amount of diluted primary antibody to each slide and place in a humidified box for incubation at 4°C overnight.
[0116] (6) Fluorescent secondary antibody: Wash the slides three times with PBST, each time for 3 min. After absorbing the excess liquid on the slides with absorbent paper, add the diluted fluorescent secondary antibody and incubate in a wet box at 20-37°C for 1 h. Wash the slides three times with PBST, each time for 3 min. All operation steps should be performed in a dark place.
[0117] (7) Nuclear re-staining: add DAPI and incubate in dark for 5 min to stain the nucleus, and wash away the excess DAPI with PBST for 5 min × 4 times;
[0118] (8) Use absorbent paper to absorb the liquid on the slide, seal the slide with a sealing solution containing an anti-fluorescence quencher, and then observe and collect images under a fluorescence microscope.
[0119] 8. Statistical analysis
[0120] Each experiment was repeated 3 times, and the mean and standard deviation were calculated. SPSS19.0 software was used for one-way analysis of variance (OneWayANOVA), and Dunnett C was used for statistical analysis when comparing each group with the control group.
[0121] 9. Experimental results
[0122] (1) Initial screening of small molecule inhibitors and structure-activity analysis
[0123] Each designed substance was dissolved in DMSO at a target final concentration of 10 mg / ml and prepared into a total tube, which was then stored in a -20°C refrigerator. The self-synthesized small molecule inhibitor and the original drug MSAB were added to the oral squamous cell carcinoma cell line CAL-27 at a compound concentration of 5 μg / ml. After 3 days of drug treatment and culture, CCK-8 detection reagent was added and the OD value of each well was detected at a wavelength of 450 nm to observe the proliferation and growth of CAL-27 in each treatment group. Referring to the experimental opinions of the "Technical Guidelines for Non-clinical Research of Cytotoxic Anti-tumor Drugs", the relative tumor proliferation rate T / C (%) was used as the experimental evaluation index for the observed experimental results. The specific evaluation criteria are: ineffective (T / C>40%, p<0.05); effective (T / C≤40%, p<0.05)
[55] .
[0124] according to Figure 3 The experimental results of group A show that at the experimental concentration (5μg / ml), the designed substance M1 in CAL-27 can effectively inhibit the proliferation of CAL-27, and the difference is statistically significant compared with the NC group. The same experiment also obtained the same results in another oral squamous cell carcinoma cell line HN6, see Figure 3 In group B, the experiments were well replicated in both cell lines.
[0125] The small molecule inhibitor was added to CAL-27 and HN6 cell lines at a concentration of 5 μg / ml, and the cells were cultured for 72 hours before taking photos under an optical microscope. Figure 4 Both cell lines treated with the self-synthesized small molecule inhibitor showed the same apoptosis phenomenon as that under the treatment of the original drug MSAB, including the overall permeability of the cells, shrinkage of the cell nucleus, and fragmentation. Group A in the figure is the CAL-27 cell line; Group B is the HN6 cell line.
[0126] (2) Study on the anti-cancer cell proliferation ability and safety of self-synthesized inhibitors in vitro
[0127] In order to further clarify the in vitro anti-proliferation activity of the effective designed compound against oral squamous cell carcinoma, we selected the two oral squamous cell carcinoma cell lines CAL-27 and HN6 as the test cells for subsequent experiments. The self-synthesized small molecule inhibitor and the original drug MSAB were added to the two oral squamous cell carcinoma cell lines using the half-logarithmic concentration dilution method, and the IC50 (unit: μg / ml) was tested after 3 days of culture.
[0128] Test results such as Figure 5 As shown in panel A, in the CAL-27 cell line, M1 (IC50 = 0.2454) has a pharmacological activity similar to that of the original drug MSAB (IC50 = 0.2238). Figure 5 As shown in Group B, in the experiment of HN6 cell line, the pharmacological activity of the self-synthesized small molecule inhibitor M1 (IC50=0.1254) was better than that of the original drug MSAB (IC50=0.1910).
[0129] At present, the application of cytotoxic anti-tumor drugs is one of the main means of drug treatment for malignant tumors. However, this type of drug will inevitably produce large toxic side effects in clinical applications, so safety research is an indispensable part of its preclinical stage. After primary drug screening and secondary screening of IC50, we finally confirmed that M1 and these three self-synthesized small molecule inhibitors have drug potential. Using the same half-logarithmic concentration dilution method, we tested the IC50 (unit: μg / ml) of this small molecule inhibitor in human gingival fibroblasts (HGF) to evaluate their safety.
[0130] Test results such as Figure 6 The IC50 values of MSAB and M1 in HGF are 5.65μM and 3.88μM respectively. The experimental results show that the IC50 values of M1 in HGF are significantly higher than those in the two cancer cell lines. Although the IC50 concentration of M1 in HGF is lower than that of the original drug MSAB, its IC50 value in cancer cell lines is also lower than that of MSAB. It has a therapeutic window similar to or even better than that of the original drug, so M1 has good drug potential.
[0131] (3) Research on the anti-cancer mechanism of self-synthesized inhibitors
[0132] In this stage of the experiment, the IC50 values of the small molecule inhibitors and the original drug in the two squamous cell carcinoma cell lines measured in the previous experiment were used to decide whether to use the two drug concentrations of 0.5μM and 1μM for subsequent experiments. The self-synthesized small molecule inhibitors and the original drug were added to the CAL-27 cells at the target final concentration, and the OD values of each group were measured regularly every day. The proliferation changes of each group of CAL-27 cells under the action of each inhibitor within 120 hours were dynamically observed, and the proliferation curves were drawn.
[0133] The results are as follows Figure 7 As shown in Group A: 24 hours after drug addition, it can be observed that the OD values of M1 and original drug groups are lower than those of NC group, indicating that the addition of inhibitors can effectively inhibit the cell proliferation of CAL-27. The observation curve shows that the inhibitory effect of each inhibitor on the proliferation of CAL-27 becomes more obvious with the passage of time and the difference is statistically significant.
[0134] The same experiment was carried out in HN6 cell line. Figure 7 As shown in Group B, no difference in OD values was observed among the groups at 24h, indicating that the cell viability of HN6 cells did not change significantly during this period, and there was a lag in the onset of action of the three compared with CAL-27; after 48h, it was observed that the OD values of M1 and the original drug group were both lower than those of the NC group, and the difference became more significant with time and was statistically significant. In addition, the experiment also observed that the self-synthesized small molecule inhibitor showed obvious concentration dependence in both cell lines.
[0135] Inducing apoptosis is one of the important ways in which anticancer drugs produce biological effects in cancer cells. In the above experiments, it can be observed under an optical microscope that with the addition of autosynthesis inhibitors, both cancer cell lines showed apoptosis. Figure 4 In order to further clarify the mechanism of action of the self-synthesized small molecule inhibitor, combined with the onset time obtained in the study, the apoptosis of CAL-27 and HN6 cells was detected by flow cytometry using 0.5 μM and 2-day treatment.
[0136] The experimental results showed that with the addition of inhibitors, the total number of apoptotic cells in both groups increased significantly compared with the NC group. Figure 8 , Fig. 9 The difference was statistically significant. The apoptosis-inducing effect of M1 was similar to that of the original drug. In addition, the experiment also found that the self-synthesized small molecule inhibitor and the original drug mainly induced late apoptosis in HN6 cells, see Fig. 9 , Figure 8 A and B are the flow cytometry test results of adding MSAB and M1 to CAL-27, E is the NC control group, and F is the quantitative statistical chart of the test results. Fig. 9 A and B are the flow cytometry test results of adding MSAB and M1 into HN6 respectively, E is the NC control group, and F is the quantitative statistical chart of the test results.
[0137] (4) Targeted research on the WNT signaling pathway
[0138] Although the above experiments have verified that M1 has good anti-proliferative ability in vitro, whether the small molecule inhibitors designed with reference to the original drug MSAB have the ability to target the WNT signaling pathway like the original drug is also worth studying.
[0139] In order to observe the effect of self-synthesized small molecule inhibitors on the activation of the WNT signaling pathway, we transfected 293T cells with TOP-Flash plasmid and treated the cells with 0.5μM and 1μM self-synthesized small molecule inhibitors, and added LiCl (5mM) to all drug-treated groups, and set up a LiCl-only group and an NC group without treatment. After 24 hours, the cells were lysed, and the activities of firefly luciferase and Renilla luciferase in the lysate were analyzed to observe the activation of the classical WNT signaling pathway.
[0140] The experimental results are as follows Fig.10 As shown in the figure, the experiment found that the self-synthesized small molecule inhibitors can inhibit the activation of LiCl on the classical WNT signaling pathway. The absorbance ratio of the experimental group was lower than that of the lithium-added group, and the difference was statistically significant. The experiment also found that the inhibitory ability of M1 on the WNT signaling pathway was similar to that of the original drug, and the inhibitory effect was close to that of the NC group.
[0141] To confirm the mechanism of action of self-synthesized small molecule inhibitors in tumor cells, we treated CAL-27 and HN6 cell lines with 0.5μM and 1μM MSAB and M1, extracted proteins, and used Western Blot to verify the protein expression in the treated cancer cells.
[0142] The experimental results are as follows Fig.11 As shown in the figure: After drug treatment, the total β-catenin expression level of the two squamous cell carcinoma cell lines did not change significantly. In CAL-27, compared with the untreated NC group, each drug-treated group could cause an increase in phosphorylated β-catenin (S33 / S37 / T41) in cancer cells at a drug concentration of 0.5μM, and showed a certain concentration dependence. While M1 and M5 had poor ability to induce β-catenin phosphorylation in HN6, when the drug concentration was increased to 1μM, an increase in the expression level of phosphorylated β-catenin was still observed, among which: Group A shows the changes in phosphorylated β-catenin and total β-catenin in CAL-27; Group B shows the changes in phosphorylated β-catenin and total β-catenin in HN6.
[0143] Related studies in the classical WNT signaling pathway suggest that abnormal nuclear translocation of β-catenin in cells is an important factor leading to cancer. To further study the effect of small molecule inhibition on nuclear translocation of β-catenin in squamous cell carcinoma cells, we treated two cancer cell lines with 0.5mM LiCl and 1μM drug concentration, and set up a lithium-only group and an NC group for 24 hours. After immunofluorescence staining, laser confocal microscopy was used to take pictures (100× magnification).
[0144] The experimental results are as follows Fig.12As shown: In CAL-27, compared with the NC group, the red-stained β-catenin in the lithium group was obviously accumulated in the cell nucleus, while the drug-added group could effectively inhibit the nuclear transfer of β-catenin in CAL-27. Group A in the figure is a photo taken under a laser confocal microscope, and Group B is the quantitative result of the cytoplasmic ratio.
[0145] In HN6 cell line Fig.12 The same experimental results can be obtained, and the differences between the lithium-only group and the drug-added group are statistically significant. Group A in the figure is a photo taken under a laser confocal microscope, and Group B is the quantitative result of the cytoplasmic ratio.
[0146] So far, the purpose of the present invention has been achieved.
[0147] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A WNT signaling inhibitor, comprising: A compound having the following structure or a pharmaceutically acceptable salt thereof: 。 2. A WNT signaling inhibitor according to claim 1, wherein the reaction raw materials are tosyl chloride and ethyl m-aminobenzoate.
Citation Information
Patent Citations
Sulfonamides and their use as a medicament
CN101578263A
WNT / b-catenin inhibitors and methods of use
US20140288174A1
LRRK2 GTP binding inhibitors for treatment of parkinson's disease and neuroinflammatory disorders
US20150361038A1
